Synairgen Stock Company Profile

Description

Synairgen plc discovers and develops drugs for respiratory diseases. It develops SNG001, an inhaled interferon beta for the treatment of COVID-19; inhaled interferon beta (IFN-ß), which is in Phase-II clinical trials for the treatment of asthma caused by the common cold and flu; IFN-ß that is in Phase-II clinical trials for the treatment or prevention of chronic obstructive pulmonary disease; and LOXL2 inhibitor for the treatment of idiopathic pulmonary fibrosis (IPF) disease. The company has a licensing and collaboration agreement with Pharmaxis Ltd. to develop a LOXL2 inhibitor. Synairgen plc was incorporated in 2004 and is headquartered in Southampton, the United Kingdom.